Cytotoxic efficacy of a novel dinuclear platinum(II) complex in human breast cancer cells

European Journal of Pharmacology

Volumn 643, Issue 1, 2010, Pages 34-41

  Bielawska, Anna ^a   Popławska, Bozena ^a   Surazyński, Arkadiusz ^a   Czarnomysy, Robert ^a   Bielawski, Krzysztof ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Breast cancer cell; Collagen biosynthesis; Dinuclear platinum complex; DNA binding; IGF I receptor; NF B signaling

Indexed keywords

BETA1 INTEGRIN; CISPLATIN; DNA TOPOISOMERASE (ATP HYDROLYSING); IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PLATINUM COMPLEX; SOMATOMEDIN C RECEPTOR;

APOPTOSIS; ARTICLE; CANCER CELL; CELL STRAIN MCF 7; CELL VIABILITY; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DNA BINDING; DRUG SPECIFICITY; DRUG STRUCTURE; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GROWTH INHIBITION; HUMAN; HUMAN CELL; METABOLIC INHIBITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; WESTERN BLOTTING;

EID: 77955056334     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.06.022     Document Type: Article

References (40)

1. Barcelo F., Ortiz-Lombardia M., Portugal J. Heterogeneous DNA binding modes of berenil. Biochim. Biophys. Acta 2001, 1519:175-184.
2. Beale P., Judson I., O'Donnell A., Trigo J., Rees C., Raynaud F., Turner A., Simmons L., Etterley L. A phase I clinical and pharmacological study of cis-diamminedichloro(2-methylpyridine) platinum II (AMD473). Br. J. Cancer 2003, 88:1128-1134.
3. Beljanski V., Marzilli L.G., Doetsch P.W. DNA damage-processing pathways involved in the eukaryotic cellular response to anticancer DNA cross-linking drugs. Mol. Pharmacol. 2004, 65:1496-1506.
4. Bielawska A., Bielawski K., Muszyńska A. Synthesis and biological evaluation of new cyclic amidine analogs of chlorambucil. Farmaco 2004, 59:111-117.
5. Bielawski K., Bielawska A., Popławska B., Bołkun-Skórnicka U. Synthesis, DNA-binding affinity and cytotoxicity of the dinuclear platinum(II) complexes with berenil and amines ligands. Acta Pol. Pharm. Drug Res. 2008, 65:363-370.
6. Brabec V., Kasparkova J. Modifications of DNA by platinum complexes: relation to resistance of tumors to platinum antitumor drugs. Drug Resist. Updat. 2005, 8:131-146.
7. Carmichael J., Degraff W., Gazdar A., Minna J., Mitchell J. Evaluation of a tetrazolinium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res. 1987, 47:936-942.
8. Choy H. Satraplatin: an orally available platinum analog for the treatment of cancer. Expert Rev. Anticancer Ther. 2006, 6:973-982.
9. Clarke P.R., Allan L.A. Cell-cycle control in the face of damage-a matter of life or death. Trends Cell Biol. 2009, 19:89-98.
10. Cohen J.J., Duke R.C., Fadok V.A., Sellins K.S. Apoptosis and programmed cell death in immunity. Annu. Rev. Immunol. 1992, 10:267-293.
11. Debart F., Periguad C., Gosselin D., Mrani D., Rayner B., Le Ber P., Auclair C., Balzarini J., De Clercq E., Paoletti C., Imbach J.L. Synthesis, DNA binding, and biological evaluation of synthetic precursors and novel analogues of netropsin. J. Med. Chem. 1989, 32:1074-1083.
12. Farrell N. Polynuclear platinum drugs. Metal ions in Biological Systems 2004, 251-296. Basel, Marcel Dekker, Inc., New York. A. Sigel, H. Sigel (Eds.).
13. Fortune J.M., Osheroff N. Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice. Prog. Nucleic Res. Mol. Biol. 2000, 64:221-253.
14. Gonzalez V.M., Amo-Ochoa P., Perez J.M., Fuertes M.A., Masaguer J.R., Navarro-Ranninger C., Alonso C. Synthesis, characterization, and DNA modification induced by a novel Pt-berenil compound with cytotoxic activity. J. Inorg. Biochem. 1996, 63:57-68.
15. Gonzalez M.G., Bhattacharya R., Hard W.G., Jones J.C.R. Transdominant regulation of integrin function: mechanisms of crosstalk. Cell. Signal. 2010, 22:578-583.
16. Gross J.M., Yee D. The type-1 insulin-like growth factor receptor tyrosine kinase and breast cancer: biology and therapeutic relevance. Cancer Metastasis Rev. 2003, 22:327-336.
17. Ioachim E., Charchanti A., Briasoulis E., Karavasilis V., Tsanou H., Arvanitis D.L. Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type IV and laminin in breast cancer: their prognostic value and role in tumour invasion and progression. Eur. J. Cancer 2002, 38:2362-2370.
18. Kasparkova J., Farrell N., Brabec V. Sequence specificity, conformation, and recognition by HMG1 protein of major DNA interstrand cross-links of antitumor dinuclear platinum complexes. J. Biol. Chem. 2000, 275:15789-15798.
19. Kasparkova J., Zehnulova J., Farrell N., Brabec V. DNA interstrand cross-links of the novel antitumor trinuclear platinum complex BBR3464. Conformation, recognition by high mobility group domain proteins, and nucleotide excision repair. J. Biol. Chem. 2002, 277:48076-48078.
20. Kim M.S., Kim S.Y., Arunachalam S., Hwang P.H., Yi H.K., Nam S.Y., Lee D.Y. C-myb stimulates cell growth by regulation of insulin-like growth factor (IGF) and IGF-binding protein-3 in K562 leukemia cells. Biochem. Biophys. Res. Commun. 2009, 385:38-43.
21. Kociecka B., Surazynski A., Miltyk W., Palka J. The effect of telmisartan on collagen biosynthesis depends on the status of estrogen activation in breast cancer cells. Eur. J. Pharmacol. 2010, 628:51-56.
22. Kumar A., Takada Y., Boriek A.M., Aggarwal B.B. Nuclear factor-κB: its role in health and disease. J. Mol. Med. 2004, 82:434-448.
23. Labat-Robert J., Robert L. Interaction between cells and extracellular matrix: signaling by integrins and the elastin-laminin receptor. Prog. Mol. Subcell. Biol. 2000, 25:57-70.
24. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227:680-685.
25. Lown J.W. Newer approaches to the study of the mechanisms of action of antitumor antibiotics. Acc. Chem. Res. 1982, 15:381-387.
26. Mamoto A., Ingber D.E. Cytoskeletal control of growth and cell fate switching. Curr. Opin. Cell Biol. 2009, 21:864-870.
27. Miltyk W., Karna E., Palka J.A. Prolidase-independent mechanism of camptothecin-induced inhibition of collagen biosynthesis in cultured human skin fibroblasts. J. Biochem. 2007, 141:287-292.
28. Neidle S. DNA minor-groove recognition by small molecules. Nat. Prod. Rep. 2001, 18:291-309.
29. Nguyen B., Hamelberg D., Bailly Ch., Colson P., Stanek J., Brun R., Neidle S., Wilson W.D. Characterization of a novel DNA minor-groove complex. Biophys. J. 2004, 86:1028-1041.
30. Oyamada I., Pałka J., Schalk E.M., Takeda K., Peterkofsky B. Scorbutic and fasted guinea pig sera contain an insulin-like growth factor I reversible inhibitor of proteoglycan and collagen synthesis in chick embryo chondrocytes and adult human skin fibroblasts. Arch. Biochem. Biophys. 1990, 276:85-93.
31. Peng D.J., Wang J., Zhou J.Y., Wu G.S. Role of the Akt/mTOR survival pathway in cisplatin resistance in ovarian cancer cells. Biochem. Biophys. Res. Commun. 2010, 394:600-605.
32. Peterkofsky B., Pałka J., Wilson S., Takeda K., Shah V. Elevated activity of low molecular weight insulin-like growth factor-binding proteins in sera of vitamin C-deficient and fasted guinea pigs. Endocrinology 1991, 128:1769-1779.
33. Portugal J. Berenil acts as a poison of eukaryotic topoisomerase II. FEBS Lett. 1994, 344:136.
34. Pugazhenthi S., Nesterova A., Sable C., Heidenreich K.A., Boxer L.M., Heasley L.E., Reusch J.E. Akt/protein kinase B up-regulates Bcl-2 expression through cAMP-response element-binding protein. J. Biol. Chem. 2000, 10761-10766.
35. Sordet O., Khan Q.A., Kohn K.W., Pommier Y. Apoptosis induced by topoisomerase inhibitors. Curr. Med. Chem. Anticancer Agents 2003, 3:271-290.
36. Vermes I., Haanen C., Steffens-Nakken H., Reutelingsperger C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J. Immunol. Meth. 1995, 184:39-51.
37. Wang J.C. Cellular roles of DNA topoisomerases: a molecular perspective. Nat. Rev. Mol. Cell Biol. 2002, 3:430-440.
38. Westermann B. Molecular machinery of mitochondrial fusion and fission. J. Biol. Chem. 2008, 283:13501-13505.
39. Wheate N.J., Collins J.G. Multi-nuclear platinum drugs: a new paradigm in chemotherapy. Curr. Med. Chem. Anticancer Agents 2005, 5:267-279.
40. Yuen J.S., Macaulay V.M. Targeting the type 1 insulin-like growth factor receptor as a treatment for cancer. Expert. Opin. Ther. Target 2008, 12:589-603.